

# Human Milk Composition

## Nutrients and Bioactive Factors

Olivia Ballard, JD<sup>a,\*</sup>, Ardythe L. Morrow, PhD, MSc<sup>b</sup>

### KEYWORDS

- Human milk composition • Breastfeeding • Infant nutrition • Pasteurization
- Bioactive factors

### KEY POINTS

- Human milk composition provides the standard for human infant nutrition, including the bioactive components that safeguard infant growth and development.
- The composition of human milk is variable within feeds, diurnally, over lactation, and between mothers and populations. This variability has benefits for infant health and survival, but for high-risk infants requiring close nutritional oversight, strategies for managing the variability of human milk feeds are needed.
- The composition of human milk can be altered with treatment of expressed milk, including its storage and pasteurization. Therefore, attention to management of expressed milk is important.

### INTRODUCTION

Exclusive human milk feeding for the first 6 months of life, with continued breastfeeding for 1 to 2 years of life or longer, is recognized as the normative standard for infant feeding.<sup>1,2</sup> Human milk is uniquely suited to the human infant, both in its nutritional composition and in the nonnutritive bioactive factors that promote survival and healthy development.<sup>3</sup> This article briefly reviews the nutritional composition of human milk

---

Disclosures: Dr Morrow has grant funding from Mead Johnson Nutrition, Inc. to study the composition of human milk. This work was supported in part by grants to Dr Morrow from the National Institute of Child Health and Human Development (P01 HD 13021 “The role of human milk in infant nutrition and health”) to study bioactive factors in human milk and from Mead Johnson Nutrition, Inc to conduct a comprehensive study of human milk factors (“The Global Exploration of Human Milk [GEHM] Study”).

<sup>a</sup> Division of Immunobiology, Center for Interdisciplinary Research in Human Milk and Lactation, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 7009, Cincinnati, OH 45229, USA; <sup>b</sup> Center for Interdisciplinary Research in Human Milk and Lactation, Perinatal Institute, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 7009, Cincinnati, OH 45229, USA

\* Corresponding author.

E-mail address: [Olivia.Ballard@cchmc.org](mailto:Olivia.Ballard@cchmc.org)

Pediatr Clin N Am 60 (2013) 49–74  
<http://dx.doi.org/10.1016/j.pcl.2012.10.002>

[pediatric.theclinics.com](http://pediatric.theclinics.com)

0031-3955/13/\$ – see front matter © 2013 Elsevier Inc. All rights reserved.

and provides an overview of its varied bioactive factors, which include cells, anti-infectious and anti-inflammatory agents, growth factors, and prebiotics. Unlike infant formula, which is standardized within a very narrow range of composition, human milk composition is dynamic, and varies within a feeding, diurnally, over lactation, and between mothers and populations. Influences on compositional differences of human milk include maternal and environmental factors and the expression and management of milk (eg, its storage and pasteurization). Understanding human milk composition provides an important tool for the management of infant feeding, particularly of fragile, high-risk infants, and for understanding the potential impact of storage and pasteurization on milk components. Furthermore, some bioactive components found in human milk are being developed and tested for potential medical applications as prophylactic or therapeutic agents.

### STAGES OF LACTATION

The first fluid produced by mothers after delivery is colostrum, which is distinct in volume, appearance, and composition. Colostrum, produced in low quantities in the first few days postpartum, is rich in immunologic components such as secretory immunoglobulin (Ig)A, lactoferrin, leukocytes, and developmental factors such as epidermal growth factor (EGF).<sup>4-6</sup> Colostrum also contains relatively low concentrations of lactose, indicating its primary functions to be immunologic and trophic rather than nutritional. Levels of sodium, chloride, and magnesium are higher and levels of potassium and calcium are lower in colostrum than in later milk.<sup>5,6</sup> As tight junction closure occurs in the mammary epithelium, the sodium to potassium ratio declines and lactose concentration increases, indicating secretory activation and the production of transitional milk. The timing of secretory activation (lactogenesis stage II) varies among women, but typically occurs over the first few days postpartum. Delayed onset of lactogenesis, defined as onset greater than 72 hours after delivery, appears to occur more often with preterm delivery and maternal obesity and may be predicted by markers of metabolic health.<sup>7,8</sup> Biochemical markers in early milk for onset of secretory activation include its sodium content, the sodium to potassium ratio, citrate, and lactose.<sup>9</sup>

Transitional milk shares some of the characteristics of colostrum but represents a period of “ramped up” milk production to support the nutritional and developmental needs of the rapidly growing infant, and typically occurs from 5 days to 2 weeks postpartum, after which milk is considered largely mature. By 4 to 6 weeks postpartum, human milk is considered fully mature. In contrast to the dramatic shift in composition observed in the first month of life, human milk remains relatively similar in composition, although subtle changes in milk composition do occur over the course of lactation.

### STUDIES OF HUMAN MILK COMPOSITION

A Medline search using only the phrase “human milk composition” reveals a steady increase in publications since the 1960s, with new components still being identified in human milk and the functionality of those components under active investigation in many laboratories worldwide. Many studies of human milk composition have been conducted in diverse populations using varied collection, storage, and testing methods. The gold standard of milk collection involves sampling of all milk expressed over 24 hours, with collection on multiple occasions from the same individuals over time.<sup>10,11</sup> This method, however, can be costly, limiting the number of participants. Alternatively, studies of milk composition can standardize collection at a specific time of day (eg, morning) by emptying the entire breast, avoiding collection from

a breast that was used for nursing within the past 2 to 3 hours, with collection on multiple occasions from the same individuals over time.<sup>12</sup> However, most published studies involve nonstandardized collection from donors to milk banks whose milk is collected at different times of day, at different timings within a feed, or at diverse stages of lactation. Studies of human milk composition also vary in their attention to storage or treatment conditions, such as the number of freeze-thaw cycles, duration of storage, or pasteurization, which may sometimes explain differing study results.

## NUTRITIONAL COMPONENTS OF HUMAN MILK

The nutritional components of human milk derive from 3 sources: some of the nutrients of milk originate by synthesis in the lactocyte, some are dietary in origin, and some originate from maternal stores. Overall the nutritional quality of human milk is highly conserved, but attention to maternal diet is important for some vitamins and the fatty acid composition of human milk (see article elsewhere in this issue by Valentine and Wagner).

### *Macronutrients*

---

The macronutrient composition of human milk varies within mothers and across lactation but is remarkably conserved across populations despite variations in maternal nutritional status.<sup>13</sup> As shown in **Table 1**, the mean macronutrient composition of mature, term milk is estimated to be approximately 0.9 to 1.2 g/dL for protein, 3.2 to 3.6 g/dL for fat, and 6.7 to 7.8 g/dL for lactose. Energy estimates range from 65 to 70 kcal/dL, and are highly correlated with the fat content of human milk. Macronutrient composition differs between preterm and term milk, with preterm milk tending to be higher in protein and fat (see **Table 1**). A study in Davis, California examined the association between maternal characteristics and the composition of human milk macronutrients<sup>10</sup> and found that after 4 months postpartum, the macronutrient concentrations of human milk are associated with 1 or more of the following factors: maternal body weight for height, protein intake, parity, return of menstruation, and nursing frequency. This study also found that mothers who produce higher quantities of milk tend to have lower milk concentrations of fat and protein but higher concentrations of lactose.

The proteins of human milk are divided into the whey and casein fractions or complexes, each comprising a remarkable array of specific proteins and peptides.<sup>14,15</sup> The most abundant proteins are casein,  $\alpha$ -lactalbumin, lactoferrin, secretory IgA (sIgA), lysozyme, and serum albumin.<sup>16,17</sup> Nonprotein nitrogen-containing compounds, including urea, uric acid, creatine, creatinine, amino acids, and nucleotides, comprise approximately 25% of human milk nitrogen. The protein content of milk obtained from mothers who deliver preterm is significantly higher than that of mothers who deliver at term (see **Table 1**). Protein levels decrease in human milk over the first 4 to 6 weeks or more of life regardless of timing of delivery (**Fig. 1**).<sup>11</sup> For feeding preterm infants, the lower level of total protein and specific amino acids from donor (typically, term, late lactation) milk alone is limiting, and requires additional supplementation (see article elsewhere in this issue by Underwood).<sup>18</sup> Concentration of human milk protein is not affected by maternal diet, but increases with maternal body weight for height, and decreases in mothers producing higher amounts of milk.<sup>10</sup>

Human milk fat is characterized by high contents of palmitic and oleic acids, the former heavily concentrated in the 2-position and the latter in the 1- and 3-positions of the triglycerides. Fat is the most highly variable macronutrient of milk. Hindmilk, defined as the last milk of a feed, may contain 2 to 3 times the concentration of milk

<b>Table 1</b> Macronutrient (g/dL) and energy (kcal/dL) composition of human milk from specified references				
Authors <sup>Ref.</sup> (year), N	Protein Mean ( $\pm 2$ SD)	Fat Mean ( $\pm 2$ SD)	Lactose Mean ( $\pm 2$ SD)	Energy Mean ( $\pm 2$ SD)
<b>Term infants, 24-h collection, mature milk</b>				
Nommsen et al <sup>10,a</sup> (1991), N = 58	1.2 (0.9, 1.5)	3.6 (2.2, 5.0)	7.4 (7.2, 7.7)	70 (57, 83)
<b>Donor human milk samples</b>				
Wojcik et al <sup>167,b</sup> (2009), N = 415	1.2 (0.7, 1.7)	3.2 (1.2, 5.2)	7.8 (6.0, 9.6)	65 (43, 87)
Michaelsen et al <sup>26,c</sup> (1990), N = 2553	0.9 (0.6, 1.4) <sup>d</sup>	3.6 (1.8, 8.9) <sup>d</sup>	7.2 (6.4, 7.6) <sup>d</sup>	67 (50,115) <sup>d</sup>
<b>Representative values of mature milk, term infants</b>				
Reference standard <sup>e</sup>	0.9	3.5	6.7	65 to 70
<b>Preterm, 24-h collection, first 8 wk of life</b>				
Bauer and Gerss <sup>11,f</sup> (2011)				
Born <29 wk, n = 52	2.2 (1.3, 3.3)	4.4 (2.6, 6.2)	7.6 (6.4, 8.8)	78 (61, 94)
Born 32–33 wk, n = 20	1.9 (1.3, 2.5)	4.8 (2.8, 6.8)	7.5 (6.5, 8.5)	77 (64, 89)
<b>Preterm donor milk</b>				
Landers and Hartmann <sup>g</sup> (2012), N = 47	1.4 (0.8, 1.9)	4.2 (2.4, 5.9)	6.7 (5.5, 7.9)	70 (53, 87)

<sup>a</sup> Davis, California: mothers at 3 months postpartum.

<sup>b</sup> United States milk bank donors.

<sup>c</sup> Danish milk bank donors.


<sup>d</sup> Median (lower 2.5 percentile, upper 97.5 percentile).

<sup>e</sup> Based on expert review: *Pediatric Nutrition Handbook*, 6th edition, Table C-1, p. 1201 (mature milk).

<sup>f</sup> Preterm infants 23 to 33 weeks' gestational age.

<sup>g</sup> Australian donor mothers of preterm infants (see article elsewhere this issue by Landers and Hartmann).

fat found in foremilk, defined as the initial milk of a feed.<sup>19</sup> A study of milk from 71 mothers over a 24-hour period found that the milk fat content was significantly lower in night and morning feedings compared with afternoon or evening feedings.<sup>20</sup> Another study found that approximately 25% of the variation in lipid concentration between mothers' milk may be explained by maternal protein intake.<sup>10</sup>



**Fig. 1.** Milk protein concentrations, comparing milk from mothers who delivered preterm and term, by gestational age at delivery and weeks postpartum. (Data from Bauer J, Gerss J. Longitudinal analysis of macronutrients and minerals in human milk produced by mothers of preterm infants. *Clin Nutr* 2011;30(2):215–20.)

The fatty acid profile of human milk varies in relation to maternal diet, particularly in the long-chain polyunsaturated fatty acids (LCPUFAs). LCPUFA intake in the Western world is skewed toward the  $\omega$ -6 fatty acids, with suboptimal intake of  $\omega$ -3 fatty acids. The docosahexaenoic acid (DHA) composition of human milk is particularly low in North American populations; supplementation should be considered for breastfeeding North American women with DHA-limited diets.<sup>18,21,22</sup>

The principal sugar of human milk is the disaccharide lactose. The concentration of lactose in human milk is the least variable of the macronutrients, but higher concentrations of lactose are found in the milk of mothers producing higher quantities of milk.<sup>10</sup> The other significant carbohydrates of human milk are the oligosaccharides, which comprise approximately 1 g/dL in human milk, depending on stage of lactation and maternal genetic factors.<sup>23–25</sup> The oligosaccharides are among the nonnutritive bioactive factors discussed later.

The mean values for macronutrients provided here, while valid, belie the observed variability of individual milk samples, particularly in their fat and protein content. Individual donor milk samples from term mothers range at least from 0.6 to 1.4 g/dL for total protein, 1.8 to 8.9 g/dL for fat, 6.4 to 7.6 g/dL for lactose, and 50 to 115 kcal/dL for energy.<sup>26</sup> Furthermore, the typical composition of preterm milk differs from that of term milk (see **Table 1**). Thus, nutritional management of high-risk infants using human milk requires individualized, adaptive or targeted, strategies for fortification, based on measurement of milk composition and growth monitoring.<sup>27</sup>

### **Micronutrients**

---

Human milk provides the normative standard for infant nutrition. Nevertheless, many micronutrients vary in human milk depending on maternal diet and body stores (see article elsewhere in this issue by Valentine and Wagner), including vitamins A, B1, B2, B6, B12, D, and iodine. The maternal diet is not always optimal, so continuing multivitamins during lactation is recommended.<sup>28,29</sup> Regardless of maternal diet, Vitamin K is extremely low in human milk and thus, the American Academy of Pediatrics recommends an injection of this vitamin to avoid hemorrhagic disease of the newborn.<sup>28</sup> Vitamin D also occurs in low quantity in human milk, particularly with low maternal exposure to sunshine, a circumstance now common in populations worldwide.<sup>30</sup> While the impact of maternal supplementation with vitamin D on milk composition is under investigation, current pediatric recommendations target postnatal vitamin D supplementation of breastfed infants. Detailed review of the micronutrient composition of human milk is not possible here, but reviews and composition tables are available elsewhere.<sup>28,29,31</sup>

### **BIOACTIVE COMPONENTS AND THEIR SOURCES**

Bioactive components of food are defined as elements that “affect biological processes or substrates and hence have an impact on body function or condition and ultimately health.”<sup>32</sup> Bioactive components in human milk come from a variety of sources; some are produced and secreted by the mammary epithelium, some are produced by cells carried within the milk,<sup>33</sup> whereas others are drawn from maternal serum and carried across the mammary epithelium by receptor-mediated transport. Furthermore, the secretion of the milk fat globule (MFG) into milk by the mammary epithelium carries with it a diverse collection of membrane-bound proteins and lipids into the milk.<sup>34</sup> Together these methods produce the variety of bioactive components in human milk. For example, in lactating women, antigen-specific B cells home to the mammary gland, where polymeric immunoglobulin receptors (pIgR) transport sIgA into the lumen of the duct.<sup>35</sup> An alternative example is vascular endothelial growth factor (VEGF), which is

found at concentrations significantly higher in milk than in maternal serum, indicating a mammary gland source.<sup>36,37</sup> Understanding the sources of bioactive components of milk also helps to explain the variability in milk concentrations that are observed following maternal use of specific medications (see article elsewhere in this issue by Rowe and colleagues).

What are the clinical implications of research on bioactive factors in human milk? The depth of scientific evidence is such that in patient or public education, it is valid to clarify that human milk is not “merely nutrition.” Rather, human milk contains a variety of factors with medicinal qualities that have a profound role in infant survival and health. Thus, safe donor milk substitutes are needed for infants at medical risk when a mother’s own milk is not available. Proteomic analysis has discovered thematic distinctions in the proteins that compose milk at differing stages of lactation, as well as differences between term and preterm milks.<sup>14,15</sup> These studies suggest that when donor milk is needed, it should be matched to the developmental stage of the infant whenever feasible, although this is often difficult in practice. Furthermore, recognition of potent, bioactive human milk factors indicates the importance of preserving their biological activity, to the extent possible, through the process of milk collection, storage, and pasteurization. Finally, recognition of the unique mechanisms by which human milk protects and enhances development provides models for new preventive and therapeutic approaches in medicine.

A complete characterization of bioactive factors of human milk is beyond the scope of this review. Here the focus is on a selected set of bioactive factors that vary between mothers of term and preterm infants, or over the course of lactation, and thus represent responsiveness to the changing needs of the infant (**Table 2**). Many of these factors act synergistically, such that consumption of human milk is superior to supplementation with individual factors or their combinations.<sup>38</sup>

## **GROWTH FACTORS**

Human milk contains numerous growth factors that have wide-ranging effects on the intestinal tract, vasculature, nervous system, and endocrine system.

### ***Intestinal Maturation and Repair: Epidermal Growth Factor***

Found in both amniotic fluid and breast milk,<sup>38–40</sup> EGF is critical to the maturation and healing of the intestinal mucosa. EGF is resistant to low pH and digestive enzymes, allowing it to pass through the stomach to the intestine, where it stimulates the enterocyte to increase DNA synthesis, cell division, absorbance of water and glucose, and protein synthesis.<sup>41,42</sup> There are multiple protective mechanisms of action for EGF in the infant intestine, including inhibition of programmed cell death, and correcting alterations in intestinal and liver tight junction proteins induced by proinflammatory tumor necrosis factor (TNF)- $\alpha$ .<sup>43</sup> Heparin-binding EGF (HB-EGF) is a member of the EGF family, and the primary growth factor responsible for damage resolution following hypoxia, ischemia-reperfusion injury, hemorrhagic shock/resuscitation injury, and necrotizing enterocolitis.<sup>44</sup> EGF is highest in early milk and decreases over lactation.<sup>45,46</sup> The average EGF level in colostrum is 2000-fold higher and in mature milk is 100-fold higher than in maternal serum.<sup>41</sup> Furthermore, preterm milk contains higher levels of EGF than does term milk.<sup>45,46</sup>

### ***Growth and Development of the Enteral Nervous System: Neuronal Growth Factors***

The immaturity of the newborn intestine extends to the enteral nervous system, which requires brain-derived neurotrophic factor (BDNF) and glial cell-line derived

**Table 2**  
Major bioactive factors in human milk

Component	Function	References
<b>Cells</b>		
Macrophages	Protection against infection, T-cell activation	Jarvinen, <sup>87</sup> 2002; Yagi, <sup>93</sup> 2010; Ichikawa, <sup>99</sup> 2003
Stem cells	Regeneration and repair	Indumathi, <sup>90</sup> 2012
<b>Immunoglobulins</b>		
IgA/sIgA	Pathogen binding inhibition	Van de Perre, <sup>35</sup> 2003; Cianga, <sup>168</sup> 1999; Brandtzaeg, <sup>124</sup> 2010; Kadaoui, <sup>125</sup> 2007; Corthésy, <sup>126</sup> 2009; Hurley, <sup>127</sup> 2011; Agarwal, <sup>94</sup> 2011; Castellote, <sup>4</sup> 2011
IgG	Antimicrobial, activation of phagocytosis (IgG1, IgG2, IgG3); anti-inflammatory, response to allergens (IgG4)	Cianga, <sup>168</sup> 1999; Agarwal, <sup>94</sup> 2011
IgM	Agglutination, complement activation	Brandtzaeg, <sup>124</sup> 2010; Van de Perre, <sup>169</sup> 1993; Agarwal, <sup>94</sup> 2011
<b>Cytokines</b>		
IL-6	Stimulation of the acute phase response, B-cell activation, proinflammatory	Ustundag, <sup>111</sup> 2005; Meki, <sup>115</sup> 2003; Mizuno, <sup>119</sup> 2012; Agarwal, <sup>94</sup> 2011; Castellote, <sup>4</sup> 2011
IL-7	Increased thymic size and output	Aspinall, <sup>110</sup> 2011; Ngom, <sup>109</sup> 2004
IL-8	Recruitment of neutrophils, proinflammatory	Claud, <sup>74</sup> 2003; Ustundag, <sup>111</sup> 2005; Meki, <sup>115</sup> 2003; Maheshwari, <sup>116</sup> 2002; Maheshwari, <sup>118</sup> 2003; Maheshwari, <sup>117</sup> 2004; Hunt, <sup>120</sup> 2012; Agarwal, <sup>94</sup> 2011; Castellote, <sup>4</sup> 2011; Mehta, <sup>170</sup> 2011
IL-10	Repressing Th1-type inflammation, induction of antibody production, facilitation of tolerance	Meki, <sup>115</sup> 2003; Agarwal, <sup>94</sup> 2011; Castellote, <sup>4</sup> 2011; Mehta, <sup>170</sup> 2011
IFN- $\gamma$	Proinflammatory, stimulates Th1 response	Hrdý, <sup>121</sup> 2012; Agarwal, <sup>94</sup> 2011
TGF- $\beta$	Anti-inflammatory, stimulation of T-cell phenotype switch	Penttila, <sup>97</sup> 2010; Kalliomäki, <sup>98</sup> 1999; Saito, <sup>99</sup> 1993; Nakamura, <sup>100</sup> 2009; Letterio, <sup>101</sup> 1994; Ando, <sup>102</sup> 2007; Ozawa, <sup>103</sup> 2009; Donnet-Hughes, <sup>104</sup> 2000; Verhasselt, <sup>171</sup> 2008; Verhasselt, <sup>172</sup> 2010; Penttila, <sup>173</sup> 2003; Mosconi, <sup>174</sup> 2010; Okamoto, <sup>175</sup> 2005; Penttila, <sup>176</sup> 2006; Peroni, <sup>160</sup> 2009; McPherson, <sup>177</sup> 2001; Ewaschuk, <sup>162</sup> 2011; Castellote, <sup>4</sup> 2011

(continued on next page)

**Table 2**  
**(continued)**

Component	Function	References
TNF- $\alpha$	Stimulates inflammatory immune activation	Rudloff, <sup>178</sup> 1992; Ustundag, <sup>111</sup> 2005; Erbağci, <sup>114</sup> 2005; Meki, <sup>115</sup> 2003; Agarwal, <sup>94</sup> 2011; Castellote, <sup>4</sup> 2011
<b>Chemokines</b>		
G-CSF	Trophic factor in intestines	Gilmore, <sup>105</sup> 1994; Gersting, <sup>106</sup> 2003; Calhoun, <sup>107</sup> 2003; Gersting, <sup>108</sup> 2004
MIF	Prevents macrophage movement, increases antipathogen activity of macrophages	Magi, <sup>179</sup> 2002; Vigh, <sup>180</sup> 2011
<b>Cytokine Inhibitors</b>		
TNFR I and II	Inhibition of TNF- $\alpha$ , anti-inflammatory	Buescher, <sup>112</sup> 1998; Buescher, <sup>113</sup> 1996; Meki, <sup>115</sup> 2003; Castellote, <sup>4</sup> 2011
<b>Growth Factors</b>		
EGF	Stimulation of cell proliferation and maturation	Patki, <sup>37</sup> 2012; Kobata, <sup>36</sup> 2008; Hirai, <sup>38</sup> 2002; Wagner, <sup>40</sup> 2008; Dvorak, <sup>45</sup> 2003; Dvorak, <sup>46</sup> 2004; Chang, <sup>42</sup> 2002; Khailova, <sup>43</sup> 2009; Coursodon, <sup>181</sup> 2012; Clark, <sup>182</sup> 2004; Castellote, <sup>4</sup> 2011; Untalan, <sup>183</sup> 2009
HB-EGF	Protective against damage from hypoxia and ischemia	Radulescu, <sup>44</sup> 2011
VEGF	Promotion of angiogenesis and tissue repair	Loui, <sup>64</sup> 2012; Ozgurtas, <sup>184</sup> 2011
NGF	Promotion of neuron growth and maturation	Rodrigues, <sup>47</sup> 2011; Boesmans, <sup>48</sup> 2008; Sánchez, <sup>49</sup> 1996; Fichter, <sup>51</sup> 2011
IGF	Stimulation of growth and development, increased RBCs and hemoglobin	Chellakooty, <sup>185</sup> 2006; Blum, <sup>52</sup> 2002; Burrin, <sup>53</sup> 1997; Philipps, <sup>54</sup> 2002; Milsom, <sup>55</sup> 2008; Prosser, <sup>56</sup> 1996; Elmlinger, <sup>57</sup> 2007; Peterson, <sup>58</sup> 2000; Murali, <sup>59</sup> 2005; Corpeleijn, <sup>60</sup> 2008; Baregamian, <sup>186</sup> 2006; Baregamian, <sup>187</sup> 2012; Büyükkayhan, <sup>61</sup> 2003; Philipps, <sup>62</sup> 2000; Kling, <sup>63</sup> 2006
Erythropoietin	Erythropoiesis, intestinal development	Carbonell-Estrany, <sup>69</sup> 2000; Juul, <sup>188</sup> 2003; Kling, <sup>70</sup> 2008; Miller-Gilbert, <sup>189</sup> 2001; Pasha, <sup>71</sup> 2008; Soubasi, <sup>68</sup> 1995; Shiou, <sup>72</sup> 2011; Arsenault, <sup>73</sup> 2010; Miller, <sup>190</sup> 2002; Untalan, <sup>183</sup> 2009

<b>Hormones</b>		
Calcitonin	Development of enteric neurons	Struck, <sup>75</sup> 2002; Wookey, <sup>76</sup> 2012
Somatostatin	Regulation of gastric epithelial growth	Rao, <sup>77</sup> 1999; Gama, <sup>78</sup> 1996
<b>Antimicrobial</b>		
Lactoferrin	Acute phase protein, chelates iron, antibacterial, antioxidant	Adamkin, <sup>129</sup> 2012; Sherman, <sup>134</sup> 2004; Manzoni, <sup>133</sup> 2009; Hirotani, <sup>191</sup> 2008; Buccigrossi, <sup>192</sup> 2007; Velona, <sup>128</sup> 1999
Lactadherin/MFG E8	Antiviral, prevents inflammation by enhancing phagocytosis of apoptotic cells	Stubbs, <sup>135</sup> 1990; Kusunoki, <sup>140</sup> 2012; Aziz, <sup>138</sup> 2011; Shi, <sup>139</sup> 2004; Chogle, <sup>141</sup> 2011; Baghdadi, <sup>142</sup> 2012; Peterson, <sup>136</sup> 1998; Newburg, <sup>137</sup> 1998; Shah, <sup>193</sup> 2012; Miksa, <sup>194</sup> 2006; Komura, <sup>195</sup> 2009; Miksa, <sup>196</sup> 2009; Wu, <sup>197</sup> 2012; Matsuda, <sup>198</sup> 2011; Silvestre, <sup>199</sup> 2005
<b>Metabolic hormones</b>		
Adiponectin	Reduction of infant BMI and weight, anti-inflammatory	Martin, <sup>80</sup> 2006; Newburg, <sup>79</sup> 2010; Woo, <sup>81</sup> 2009; Woo, <sup>200</sup> 2012; Ley, <sup>201</sup> 2011; Dundar, <sup>202</sup> 2010; Ozarda, <sup>203</sup> 2012; Savino, <sup>83</sup> 2008; Weyermann, <sup>204</sup> 2007
Leptin	Regulation of energy conversion and infant BMI, appetite regulation	Savino, <sup>83</sup> 2008; Savino, <sup>82</sup> 2012; Palou, <sup>84</sup> 2009; Weyermann, <sup>204</sup> 2007
Ghrelin	Regulation of energy conversion and infant BMI	Savino, <sup>83</sup> 2008; Savino, <sup>82</sup> 2012; Dundar, <sup>85</sup> 2010
<b>Oligosaccharides &amp; glycans</b>		
HMOS	Prebiotic, stimulating beneficial colonization and reducing colonization with pathogens; reduced inflammation	Newburg, <sup>23</sup> 2005; Morrow, <sup>24</sup> 2005; DeLeoz, <sup>153</sup> 2012; Marcoba, <sup>205</sup> 2012; Kunz, <sup>206</sup> 2012; Ruhaak, <sup>207</sup> 2012; Bode, <sup>152</sup> 2012
Gangliosides	Brain development; anti-infectious	Wang B, <sup>208</sup> 2012
Glycosaminoglycans	Anti-infectious	Coppa, <sup>209</sup> 2012; Coppa, <sup>210</sup> 2011
<b>Mucins</b>		
MUC1	Blocks infection by viruses and bacteria	Ruvoen-Clouet, <sup>146</sup> 2006; Liu, <sup>151</sup> 2012; Sando, <sup>211</sup> 2009; Saeland, <sup>148</sup> 2009; Yolken, <sup>149</sup> 1992
MUC4	Blocks infection by viruses and bacteria	Ruvoen-Clouet, <sup>146</sup> 2006; Liu, <sup>151</sup> 2012; Chaturvedi, <sup>212</sup> 2008

**Abbreviations:** BMI, body mass index; EGF, epidermal growth factor; G-CSF, granulocyte-colony stimulating factor; HB-EGF, heparin-binding epidermal growth factor; HMOS, human milk oligosaccharides; IFN, interferon; Ig, immunoglobulin; IGF, insulin-like growth factor; IL, interleukin; MFG, milk fat globule; MIF, macrophage migratory inhibitory factor; MUC, mucin; NGF, nerve growth factor; RBCs, red blood cells; sig, secretory Ig; TGF, transforming growth factor; Th1, T-helper cell 1; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; VEGF, vascular endothelial growth factor.

neurotrophic factor (GDNF) for its development.<sup>47</sup> BDNF can enhance peristalsis, a function frequently impaired in the preterm gut.<sup>48</sup> Rodents that lack GDNF display a profound loss of neurons in the enteric nervous system.<sup>49</sup> BDNF, GDNF, and a related protein, ciliary neurotrophic factor (CNTF), are detected in human milk up to 90 days after birth.<sup>50,51</sup> In human cells, breast milk-derived GDNF increases neuron survival and outgrowth.<sup>51</sup>

### ***Tissue Growth: the Insulin-Like Growth Factor Superfamily***

---

Insulin-like growth factor (IGF)-I and IGF-II, as well as IGF binding proteins and IGF-specific proteases, are found in human milk.<sup>52–54</sup> Levels are highest in colostrum, and steadily decline over the course of lactation.<sup>55,56</sup> There are no significant differences between preterm and term milk, with the exception of IGF binding protein 2, which is higher in preterm milk.<sup>52,57</sup> In rodents, administration of human IGF-I during surgical stress/total parental nutrition causes increased tissue growth<sup>58</sup> and attenuates intestinal atrophy,<sup>59</sup> although no human trial has been conducted.<sup>60</sup> IGF-1 may also play a role in the survival of enterocytes following intestinal damage from oxidative stress.<sup>57</sup> Breastfed infants have higher circulating IGF-I in the serum.<sup>61</sup> IGF can be taken up in a bioactive form by intestines and transported into the blood.<sup>54,62</sup> The function of absorbed IGF has not been fully detailed, but enteral administration of physiologic levels of IGF-I stimulates erythropoiesis and increases hematocrit.<sup>63</sup>

### ***Regulation of the Vascular System: Vascular Endothelial Growth Factor***

---

Angiogenesis is regulated primarily by the relative expression of VEGF and its antagonists. VEGF concentration is highest in colostrum in both preterm and term human milk, with preterm milk containing less VEGF than term milk.<sup>64</sup> In retinopathy of prematurity (ROP), it is thought that pulmonary immaturity, supplemental oxygen, and negative regulation of VEGF lead to dysregulated vascularization of the retina,<sup>65,66</sup> suggesting a mechanism by which human milk may help reduce the burden of ROP.

### ***Intestinal Development and Prevention of Anemia: Erythropoietin***

---

Milk contains significant quantities of erythropoietin (Epo), which is the primary hormone responsible for increasing red blood cells (RBCs). Blood loss, intestinal pathology, and immaturity of the hematopoietic system all contribute to anemia of prematurity, which profoundly affects growth and development.<sup>67</sup> Thus some suggest that Epo may help prevent anemia of prematurity,<sup>68</sup> but administration of Epo has shown mixed results.<sup>69</sup> Administration of Epo in conjunction with iron, however, may increase hemoglobin and hematocrit levels.<sup>70</sup> A small trial of enteral Epo in preterm infants showed increased serum and reticulocyte levels.<sup>71</sup> In addition, Epo is an important trophic factor and tightens intestinal junctions.<sup>72</sup> There is some evidence that Epo may help protect against mother-to-child transmission of human immunodeficiency virus (HIV),<sup>73</sup> and may reduce the risk of necrotizing enterocolitis.<sup>72,74</sup>

### ***Growth-Regulating Hormones: Calcitonin and Somatostatin***

---

Calcitonin and its precursor procalcitonin are present in large quantities in milk.<sup>75</sup> Enteric neurons express the calcitonin receptor immunoreactivity from late gestation into infancy.<sup>76</sup> Somatostatin is rapidly degraded in the jejunum and is not transferred through the intestinal wall, but delivery with milk protects it from degradation and maintains bioactivity within the lumen.<sup>77</sup> Somatostatin normally inhibits growth factors, but its role in human milk remains unclear.<sup>78</sup>

### ***Regulating Metabolism and Body Composition: Adiponectin and Other Hormones***

---

Adiponectin is a large, multifunctional hormone that actively regulates metabolism and suppresses inflammation. Found in large quantities in human milk, adiponectin can cross the intestinal barrier, and appears to modify infant metabolism.<sup>79,80</sup> Levels of adiponectin in milk correlate inversely with infant weight and body mass index while exclusively breastfeeding, leading to the proposal by some that adiponectin in human milk may contribute to reduced incidence of overweight and obesity in later life, although this remains to be determined.<sup>79,81</sup> Other metabolism-regulating hormones found in effective quantities in human milk are leptin, resistin, and ghrelin, which appear to play an important role in regulating energy conversion, body composition, and appetite control.<sup>82–85</sup>

### **IMMUNOLOGIC FACTORS**

Feeding human milk protects against infection and inflammation,<sup>86</sup> and early milk is enriched in immune factors that help to ensure infant survival.<sup>15</sup> The specific protective components of human milk are so numerous and multifunctional that science is just beginning to understand their functions.

### ***Transfer of Living Protection and Programming: Cells of Human Milk***

---

Human milk contains a variety of cells, including macrophages, T cells, stem cells, and lymphocytes.<sup>87–93</sup> In early lactation, the breastfed infant may consume as many as  $10^{10}$  maternal leukocytes per day. The relative quantity of these cells differs among mothers and is reported to differ in the milk of infants who develop allergy.<sup>87</sup> About 80% of the cells in early milk are breast milk macrophages, which originate as peripheral blood monocytes that exit the bloodstream and migrate into milk through the mammary epithelium. Phagocytosis of human milk components transforms these monocytes into potent breast milk macrophages with unique functional features, including the ability to differentiate into dendritic cells that stimulate infant T-cell activity.<sup>89,93</sup> This capability provides broadly powerful protection against pathogens while stimulating development of the infant's own immune system. In women infected with HIV-1 and human T-lymphotropic virus 1; however, the activity of these cells unfortunately enables mother-to-infant viral transmission (see article elsewhere in this issue by Lawrence). Stem cells have also been identified in human milk<sup>88,90</sup>; their function is under investigation.

### ***Communication Between Cells: Cytokines and Chemokines***

---

Cytokines are multifunctional peptides that act in an autocrine/paracrine fashion.<sup>33</sup> Chemokines are a special class of chemotactic cytokines that induce movement of other cells. Human milk cytokines can cross the intestinal barrier, where they “communicate” with cells to influence immune activity. While many cytokines and chemokines have multiple functions, milk-borne cytokines may be grouped broadly into those that enhance inflammation or defend against infection, and those that reduce inflammation. A complete review of the cytokines of human milk is available elsewhere.<sup>33,94–96</sup>

The transforming growth factor (TGF)- $\beta$  family constitute the most abundant cytokines of human milk and consist of 3 isoforms, of which TGF- $\beta$ 2 predominates.<sup>97–99</sup> Milk-borne TGF- $\beta$  regulates inflammation and wound repair, and helps prevent allergic diseases. TGF- $\beta$  is converted to its active form by the low pH of the stomach.<sup>100</sup> Only 15 minutes after TGF- $\beta$ 1-deficient mouse pups are suckled by heterozygous dams, TGF- $\beta$ 1 is measurable in the pup's serum and tissue.<sup>101</sup> Milk TGF- $\beta$  has

tolerance-enhancing activity in the intestinal tract,<sup>100,102–104</sup> a proposed mechanism for its antiallergenic effects.

Granulocyte-colony stimulating factor (G-CSF), identified in human milk decades ago,<sup>105</sup> has beneficial effects on intestinal development and the treatment of sepsis. While milk-borne G-CSF survives transit through the stomach, it is not appreciably absorbed and acts at the intestinal surface,<sup>106,107</sup> where it increases villi, crypt depth, and cell proliferation.<sup>108</sup> Other regulatory cytokines found in milk are interleukin (IL)-10 and IL-7<sup>109</sup>; milk-borne IL-7 is known to cross the intestinal wall and influence thymic development.<sup>110</sup>

Proinflammatory cytokines TNF- $\alpha$ , IL-6, IL-8, and interferon (IFN)- $\gamma$  are also found in mother's milk, generally at lower levels and decreasing over lactation.<sup>4,111</sup> The levels of these cytokines in milk are also associated with the timing of delivery.<sup>4,111</sup> Intriguingly, soluble TNF receptors I and II, which neutralize TNF- $\alpha$ , also are found in human milk.<sup>112</sup> Thus, most TNF- $\alpha$  may be bound and not freely active in milk.<sup>113</sup> Both IL-8 and TNF- $\alpha$  are modestly increased in mature milk of mothers who have had preeclampsia.<sup>114</sup> Levels of TNF- $\alpha$  correlate positively with those of other inflammatory cytokines.<sup>115</sup> IL-6 is associated with systemic inflammation and fever.<sup>115</sup> The role of the inflammatory cytokines found in human milk remains under investigation, but they are known to be engaged in the recruitment of neutrophils and to enhance intestinal development, while IL-8 may help protect against TNF- $\alpha$ -mediated damage.<sup>116–118</sup> Higher levels of IL-6 and IL-8 occur in mastitis, with higher cytokine levels confined to only the affected lobes.<sup>119,120</sup> IFN- $\gamma$  has also been widely studied because of its proinflammatory role; IFN- $\gamma$  enhances the T-helper (Th)1/inflammation response while suppressing the Th2/allergic response.<sup>94</sup> The colostrum of allergic mothers contains lower IFN- $\gamma$  but higher Th2 cytokines IL-4 and IL-13 compared with the colostrum of nonallergic mothers.<sup>121</sup>

### ***Protection from Infection: Acquired and Innate Factors***

A recent study in Nepal found a 9-fold increase in risk of diarrhea in children who were not breastfed,<sup>122</sup> consistent with previous global studies.<sup>123</sup> Infants are born with immature adaptive immunity, and rely on maternal antibodies for defense against pathogens.<sup>124</sup> Human milk sIgA-antigen complexes are taken up and processed by intestinal dendritic cells, which allows for antigen recognition while maintaining a non-inflammatory environment.<sup>125</sup> While sIgA is the predominant antibody of human milk, milk also contains IgM and IgG, the latter becoming more abundant in later lactation.<sup>15</sup> A comprehensive review of human milk immunoglobulins is available elsewhere.<sup>124,126,127</sup>

A set of innate, multifunctional molecules known as defensins also provide significant protection against infection. These molecules are typically highest in colostrum, and decrease over lactation. Among the most abundant of these is lactoferrin, an iron-binding glycoprotein belonging to the transferrin family,<sup>128,129</sup> which is effective against many different bacteria, viruses, and fungi.<sup>130–134</sup> Another glycoprotein, lactadherin, was initially identified in the MFG.<sup>135</sup> Milk-borne lactadherin survives transit through the stomach<sup>136</sup> and prevents rotaviral infection in the newborn.<sup>137</sup> Following infection or damage, lactadherin mediates phagocytic uptake of apoptotic cells<sup>138,139</sup> and stimulates a signaling cascade that results in decreased inflammation via blockade of toll-like receptor 4 and nuclear factor  $\kappa$ B signaling.<sup>138,140</sup> Lactadherin promotes healing during intestinal inflammation<sup>140,141</sup> and a tolerogenic phenotype in intestinal dendritic cells and macrophages,<sup>138,142</sup> which is important in maintaining gut health. Another multifunctional protein, bile salt-stimulating lipase (BSSL),<sup>143</sup> is a highly glycosylated enzyme that breaks down milk fats, thereby releasing their energy for infant metabolism. Milk-borne BSSL also protects infants from viral

infection, including Norwalk virus and HIV. BSSL binds to dendritic cells, preventing HIV transinfection of CD4<sup>+</sup> T cells.<sup>144,145</sup> The bioactive region of BSSL is modified by the glycans present, which change with maternal genetics and over lactation.<sup>143,146</sup>

The MFG contains mucins (MUC1, MUC4, and potentially others) derived from the maternal plasma membrane.<sup>147</sup> These mucins are multifunctional, but most importantly protect infants from infection. For example, MUC1 blocks infection by HIV and rotavirus<sup>148,149</sup> and both MUC1 and MUC4 block infection by *Salmonella enterica* serovar *typhimurium* and Norwalk virus.<sup>146,150,151</sup>

### ***Selection for the Growth of Beneficial Organisms: Oligosaccharides***

---

The human milk oligosaccharides (HMOS) range from 3 to 32 sugars in size, and differ in composition from those of any other mammal.<sup>23,24</sup> Though nonnutritive to the infant, HMOS constitute a remarkable quantity of human milk, similar to the quantity of total protein. These structures are synthesized by glycosyltransferases, enzymes that also synthesize similar structures in other human secretions and on mucosal surfaces. The HMOS are prebiotic agents that selectively encourage the growth of beneficial (probiotic) organisms. In addition, the HMOS and their protein conjugates are recognized as pathogen-binding inhibitors that function as soluble “decoy” receptors for pathogens that have an affinity for binding to oligosaccharide receptors expressed on the infant’s intestinal surface. Mothers vary in the specific structures of HMOS in their milk as a result of genetic differences similar to blood group types.<sup>23–25</sup> This variation in HMOS composition, unlike blood group types, does not create incompatibility, so that all mothers may be considered “universal donors.” Rather, the variation in HMOS composition among mothers is thought to promote human survival, as pathogens differ in their affinity for binding to specific oligosaccharides. Protection by some forms of HMOS but not others has been shown in relation to diarrhea caused by specific pathogens<sup>23,24</sup> and HIV.<sup>152</sup> The apparent differences in lactose and HMOS composition of preterm milk requires further investigation.<sup>25,153</sup>

It was long believed that human milk was sterile, but it is now recognized that human milk harbors a microbial community, the composition of which appears to change with maternal characteristics and over the course of lactation.<sup>154,155</sup> The HMOS influence intestinal colonization and may also influence the composition of the bacterial community in milk.

### **IMPACT OF STORAGE AND PASTEURIZATION ON MILK COMPONENTS**

Increasingly, human milk feeding occurs apart from feeding at the mother’s breast. Most lactating women in North America now express and store their milk at some time.<sup>156</sup> Varying degrees of nutrient loss occurs, depending on the nutrient and the storage methods. For vitamin C loss occurs rapidly, even during the process of feeding freshly expressed human milk by bottle.<sup>155</sup> For multiple human milk components, however, significant degradation may occur only with long-term storage and freeze-thaw cycles, which tend to reduce bactericidal capacity. The Academy of Breastfeeding Medicine protocol for home storage of human milk can be used to guide mothers in these activities to optimize the integrity of expressed and stored milk (see article elsewhere in this issue by Chanry and Howard).

Another major movement has been the development of milk sharing via donor human milk banks or alternatively via Internet milk sharing (see article elsewhere in this issue by Landers and Hartmann). Because of the perceived risk of transmitting pathogens via human milk, a variety of protocols have been developed for pasteurization of donor milk, including: high-temperature short-time (HTST) heating (72°C for

15 seconds); Holder pasteurization (62.5°C for 30 minutes, a low-temperature long-time [LTLT] method); and flash heating (a low-tech HTST method that involves heating a jar of milk in a water bath, which is rapidly brought to a rolling boil, before milk is removed and rapidly cooled). Flash heating was developed with the goal of achieving effective pasteurization in a home environment in resource-poor areas of the world to prevent transmission of HIV.

Each pasteurization method has been investigated for its ability to eliminate pathogens while preserving as many bioactive components and nutrients as possible.<sup>157–159</sup> Unfortunately, heat treatment of human milk reduces the concentration and functionality of its bioactive components, particularly in protein composition and function. Significant reductions have been demonstrated after pasteurization in sIgA, lysozyme, BSSL, cytokines, lipases, TGF- $\beta$ , and adiponectin, among other proteins.<sup>160–162</sup> Pasteurization damages some proteins more than others,<sup>162</sup> but is particularly damaging when paired with the multiple freeze-thaw cycles that can occur with donated milk.<sup>163</sup> The degree of impact appears to vary by pasteurization method. Boiling is likely the most damaging, while Holder pasteurization, the method used by the milk banks associated with the Human Milk Banking Association of North America, may be more destructive than HTST (see article elsewhere in this issue by Landers and Hartmann). Though a low-tech method, flash-heat treatment appears to preserve the bacteriostatic activity of human milk.<sup>158</sup> Much work remains to be done regarding the bioactivity of human milk components following milk treatment.<sup>162</sup>

## **HUMAN MILK COMPONENTS IN RELATION TO INFANT HEALTH**

### ***Management or Augmentation of Human Milk Factors***

---

Recognition of the dynamic variability of human milk is important to the management of human milk feeding. For example, mothers of term infants are commonly advised to empty an entire breast before feeding from the other breast. As hindmilk is more energy dense because of its higher lipid content, this recommendation ensures that infant satiety and energy needs for growth are well met. Hindmilk has been successfully used to improve growth of very premature infants, and is recommended for their nutritional management.<sup>164</sup> Furthermore, understanding the dynamic variability of human milk, donor milk banks have established protocols for pooling different milk donations to achieve more uniform milk for distribution.

Some milk factors can be modified through dietary intake or exposures to optimize infant growth and health. For example, maternal diet influences the DHA content of milk, which is below recommended levels in many populations. Valentine<sup>164</sup> has shown that maternal supplementation with 1 g of preformed DHA daily significantly increases milk DHA levels, which thereby improves the dietary DHA of breastfed infants. Another approach to modification of human milk is through maternal immunization, which is being actively pursued as a public health strategy. Trials of maternal immunization have demonstrated significant increases in the level of protective immunoglobulins in milk and have dramatically reduced influenza in mothers and infants.<sup>165</sup>

### ***Potential Novel Therapeutics Based on Human Milk Components***

---

The important maternal act of breastfeeding provides many bioactive components to infants. Some of these components have been proposed as novel medical agents for prevention or treatment of disease, including lactoferrin, lactadherin, EGF, Epo, and HMOS. While various human milk components have demonstrated significant biological activity *in vitro* or *in vivo*, only a few have been tested in human clinical trials to improve specific health outcomes. One of the most studied of these factors is

lactoferrin. Testing lactoferrin as a novel medical agent has been advanced by the use of recombinant bovine lactoferrin, owing to its high homology with human lactoferrin. An Italian study of preterm infants found that supplementation with bovine lactoferrin, alone or in combination with *Lactobacillus casei* subsp *rhamnosus*, significantly reduced the risk of late-onset sepsis.<sup>133,134</sup> A current phase 1/2 trial is evaluating the safety and efficacy of an oral lactoferrin solution to prevent infection in preterm infants.<sup>161</sup> Many other individual milk components may be tested in future for specific applications, but human milk remains the unique and potent standard for feeding infants.

## SUMMARY

Human milk is a dynamic, multifaceted fluid containing nutrients and bioactive factors needed for infant health and development. Its composition varies by stage of lactation and between term and preterm infants. While many studies of human milk composition have been conducted, components of human milk are still being identified. Standardized, multipopulation studies of human milk composition are sorely needed to create a rigorous, comprehensive reference inclusive of nutrients and bioactive factors. Nevertheless, knowledge of human milk composition is increasing, leading to greater understanding of the role of human milk in infant health and development.<sup>166</sup>

## ACKNOWLEDGMENTS

The authors gratefully acknowledge Donna Wuest for assistance with manuscript preparation.

## REFERENCES

1. Section on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics* 2012;129(3):e827–41.
2. WHO. Infant and young child nutrition. Geneva (Switzerland): WHO; 2003.
3. Oftedal OT. The evolution of milk secretion and its ancient origins. *Animal* 2012; 6(3):355–68.
4. Castellote C, Casillas R, Ramirez-Santana C, et al. Premature delivery influences the immunological composition of colostrum and transitional and mature human milk. *J Nutr* 2011;141(6):1181–7.
5. Pang WW, Hartmann PE. Initiation of human lactation: secretory differentiation and secretory activation. *J Mammary Gland Biol Neoplasia* 2007;12(4):211–21.
6. Kulski JK, Hartmann PE. Changes in human milk composition during the initiation of lactation. *Aust J Exp Biol Med Sci* 1981;59(1):101–14.
7. Henderson JJ, Hartmann PE, Newnham JP, et al. Effect of preterm birth and antenatal corticosteroid treatment on lactogenesis II in women. *Pediatrics* 2008;121(1):e92–100.
8. Nommsen-Rivers LA, Dolan LM, Huang B. Timing of stage II lactogenesis is predicted by antenatal metabolic health in a cohort of primiparas. *Breastfeed Med* 2012;7(1):43–9.
9. Cregan MD, De Mello TR, Kershaw D, et al. Initiation of lactation in women after preterm delivery. *Acta Obstet Gynecol Scand* 2002;81(9):870–7.
10. Nommsen LA, Lovelady CA, Heinig MJ, et al. Determinants of energy, protein, lipid, and lactose concentrations in human milk during the first 12 mo of lactation: the DARLING Study. *Am J Clin Nutr* 1991;53(2):457–65.

11. Bauer J, Gersts J. Longitudinal analysis of macronutrients and minerals in human milk produced by mothers of preterm infants. *Clin Nutr* 2011;30(2):215–20.
12. Geraghty SR, Davidson BS, Warner BB, et al. The development of a research human milk bank. *J Hum Lact* 2005;21(1):59–66.
13. Prentice A. Regional variations in the composition of human milk. In: Jensen RG, editor. *Handbook of milk composition*. San Diego (CA): Academic Press, Inc; 1995. p. 919.
14. Liao Y, Alvarado R, Phinney B, et al. Proteomic characterization of human milk whey proteins during a twelve-month lactation period. *J Proteome Res* 2011; 10(4):1746–54.
15. Gao X, McMahon RJ, Woo JG, et al. Temporal changes in milk proteomes reveal developing milk functions. *J Proteome Res* 2012;11(7):3897–907.
16. Lonnerdal B. Human milk proteins: key components for the biological activity of human milk. *Adv Exp Med Biol* 2004;554:11–25.
17. Jensen RG. *Handbook of milk composition*. San Diego (CA): Academic Press, Inc; 1995.
18. Valentine CJ, Morrow G, Fernandez S, et al. Docosahexaenoic acid and amino acid contents in pasteurized donor milk are low for preterm infants. *J Pediatr* 2010;157(6):906–10.
19. Saarela T, Kokkonen J, Koivisto M. Macronutrient and energy contents of human milk fractions during the first six months of lactation. *Acta Paediatr* 2005;94(9): 1176–81.
20. Kent JC, Mitoulas LR, Cregan MD, et al. Volume and frequency of breastfeedings and fat content of breast milk throughout the day. *Pediatrics* 2006;117(3):e387–95.
21. Valentine CJ, Morrow G, Pennell M, et al. Randomized controlled trial of docosahexaenoic acid supplementation in midwestern U.S. Human milk donors. *Breastfeed Med* 2012. <http://dx.doi.org/10.1089/bfm.2011.0126>.
22. Martin MA, Lassek WD, Gaulin SJ, et al. Fatty acid composition in the mature milk of Bolivian forager-horticulturalists: controlled comparisons with a US sample. *Matern Child Nutr* 2012;8(3):404–18.
23. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. *Annu Rev Nutr* 2005;25:37–58.
24. Morrow AL, Ruiz-Palacios GM, Jiang X, et al. Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. *J Nutr* 2005;135(5):1304–7.
25. Gabrielli O, Zampini L, Galeazzi T, et al. Preterm milk oligosaccharides during the first month of lactation. *Pediatrics* 2011;128(6):e1520–31.
26. Michaelsen KF, Skafte L, Badsberg JH, et al. Variation in macronutrients in human bank milk: influencing factors and implications for human milk banking. *J Pediatr Gastroenterol Nutr* 1990;11(2):229–39.
27. Arslanoglu S, Moro GE, Ziegler EE, The WAPM Working Group on Nutrition. Optimization of human milk fortification for preterm infants: new concepts and recommendations. *J Perinat Med* 2010;38(3):233–8.
28. Greer FR. Do breastfed infants need supplemental vitamins? *Pediatr Clin North Am* 2001;48(2):415–23.
29. Allen LH. B vitamins in breast milk: relative importance of maternal status and intake, and effects on infant status and function. *Adv Nutr* 2012;3(3):362–9.
30. Dawodu A, Zalla L, Woo JG, et al. Heightened attention to supplementation is needed to improve the vitamin D status of breastfeeding mothers and infants when sunshine exposure is restricted. *Matern Child Nutr* 2012. <http://dx.doi.org/10.1111/j.1740-8709.2012.00422.x>.

31. American Academy of Pediatrics. Pediatric nutrition handbook. 6th edition. Elk Gove Village (IL): American Academy of Pediatrics; 2009.
32. Schrezenmeir J, Korhonen H, Williams C, et al. Foreword. *Br J Nutr* 2000;84(S1):1.
33. Garofalo R. Cytokines in human milk. *J Pediatr* 2010;156(Suppl 2):S36–40.
34. Cavaletto M, Giuffrida MG, Conti A. The proteomic approach to analysis of human milk fat globule membrane. *Clin Chim Acta* 2004;347(1–2):41–8.
35. Van de Perre P. Transfer of antibody via mother's milk. *Vaccine* 2003;21(24):3374–6.
36. Kobata R, Tsukahara H, Ohshima Y, et al. High levels of growth factors in human breast milk. *Early Hum Dev* 2008;84(1):67–9.
37. Patki S, Patki U, Patil R, et al. Comparison of the levels of the growth factors in umbilical cord serum and human milk and its clinical significance. *Cytokine* 2012;59(2):305–8.
38. Hirai C, Ichiba H, Saito M, et al. Trophic effect of multiple growth factors in amniotic fluid or human milk on cultured human fetal small intestinal cells. *J Pediatr Gastroenterol Nutr* 2002;34:524–8.
39. Chailier P, Menard D. Ontogeny of EGF receptors in the human gut. *Front Biosci* 1999;4:87–101.
40. Wagner CL, Taylor SN, Johnson D. Host factors in amniotic fluid and breast milk that contribute to gut maturation. *Clin Rev Allergy Immunol* 2008;34:191–204.
41. Read LC, Upton FM, Francis GL, et al. Changes in the growth-promoting activity of human milk during lactation. *Pediatr Res* 1984;18(2):133–9.
42. Chang CJ, Chao JC. Effect of human milk and epidermal growth factor on growth of human intestinal caco-2 cells. *J Pediatr Gastroenterol Nutr* 2002;34:394–401.
43. Khailova L, Dvorak K, Arganbright KM, et al. Changes in hepatic cell junctions structure during experimental necrotizing enterocolitis: effect of EGF treatment. *Pediatr Res* 2009;66(2):140–4.
44. Radulescu A, Zhang H-Y, Chen C-L, et al. Heparin-binding EGF-like growth factor promotes intestinal anastomotic healing. *J Surg Res* 2011;171:540–50.
45. Dvorak B, Fituch CC, Williams CS, et al. Increased epidermal growth factor levels in human milk of mothers with extremely premature infants. *Pediatr Res* 2003;54(1):15–9.
46. Dvorak B, Fituch CC, Williams CS, et al. Concentrations of epidermal growth factor and transforming growth factor-alpha in preterm milk. *Advances in experimental medicine and biology* 2004;554:407–9.
47. Rodrigues D, Li A, Nair D, et al. Glial cell line-derived neurotrophic factor is a key neurotrophin in the postnatal enteric nervous system. *Neurogastroenterol Motil* 2011;23:e44–56.
48. Boesmans W, Gomes P, Janssens J, et al. Brain-derived neurotrophic factor amplifies neurotransmitter responses and promotes synaptic communication in the enteric nervous system. *Gut* 2008;57:314–22.
49. Sánchez M, Silos-Santiago I, Frisén J, et al. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. *Nature* 1996;382(6586):70–3.
50. Li R, Xia W, Zhang Z, et al. S100B protein, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in human milk. *PLoS One* 2011;6(6):e21663.
51. Fichter M, Klotz M, Hirschberg DL, et al. Breast milk contains relevant neurotrophic factors and cytokines for enteric nervous system development. *Mol Nutr Food Res* 2011;55:1592–6.

52. Blum JW, Baumrucker CR. Colostral and milk insulin-like growth factors and related substances: mammary gland and neonatal (intestinal and systemic) targets. *Domest Anim Endocrinol* 2002;23:101–10.
53. Burrin DG. Is milk-borne insulin-like growth factor-I essential for neonatal development? *J Nutr* 1997;127:975S–9S.
54. Philipps AF, Kling PJ, Grille JG, et al. Intestinal transport of insulin-like growth factor-I (IGF-I) in the suckling rat. *J Pediatr Gastroenterol Nutr* 2002;35:539–44.
55. Milsom SR, Blum WF, Gunn AJ. Temporal changes in insulin-like growth factors I and II and in insulin-like growth factor binding proteins 1, 2, and 3 in human milk. *Horm Res* 2008;69:307–11.
56. Prosser CG. Insulin-like growth factors in milk and mammary gland. *J Mammary Gland Biol Neoplasia* 1996;1(3):297–306.
57. Emlinger MW, Hochhaus F, Loui A, et al. Insulin-like growth factors and binding proteins in early milk from mothers of preterm and term infants. *Horm Res* 2007;68:124–31.
58. Peterson CA, Gillingham MB, Mohapatra NK, et al. Enterotrophic effect of insulin-like growth factor-I but not growth hormone and localized expression of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and -5 mRNAs in jejunum of parenterally fed rats. *JPEN J Parenter Enteral Nutr* 2000;24(5):288–95.
59. Murali SG, Nelson DW, Draxler AK, et al. Insulin-like growth factor-I (IGF-I) attenuates jejunal atrophy in association with increased expression of IGF-I binding protein-5 in parenterally fed mice. *J Nutr* 2005;135(11):2553–9.
60. Corpeleijn WE, van Vliet I, de Gast-Bakker DA, et al. Effect of enteral IGF-1 supplementation on feeding tolerance, growth, and gut permeability in enterally fed premature neonates. *J Pediatr Gastroenterol Nutr* 2008;46:184–90.
61. Büyükkayhan D, Tanzer F, Erselcan T, et al. Umbilical serum insulin-like growth factor 1 (IGF-1) in newborns: effects of gestational age, postnatal age, and nutrition. *Int J Vitam Nutr Res* 2003;73(5):343–6.
62. Philipps AF, Dvorak B, Kling PJ, et al. Absorption of milk-borne insulin-like growth factor-I into portal blood of suckling rats. *J Pediatr Gastroenterol Nutr* 2000;31:128–35.
63. Kling PJ, Taing KM, Dvorak B, et al. Insulin-like growth factor-I stimulates erythropoiesis when administered enterally. *Growth Factors* 2006;24(3):218–23.
64. Loui A, Eilers E, Strauss E, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF Receptor 1 (Sflt-1) levels in early and mature human milk from mothers of preterm versus term infants. *J Hum Lact* 2012;28(4):522–8.
65. Reynolds JD. The management of retinopathy of prematurity. *Paediatr Drugs* 2001;3(4):263–72.
66. DiBiasie A. Evidence-based review of retinopathy of prematurity prevention in VLBW and ELBW infants. *Neonatal Netw* 2006;25(6):393–403.
67. Kett JC. Anemia in infancy. *Pediatr Rev* 2012;33(4):186–7.
68. Soubasi V, Kremenopoulos G, Diamanti E, et al. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. *J Pediatr* 1995;127:291–7.
69. Carbonell-Estrany X, Figueras-Aloy J, Alvarez E. Erythropoietin and prematurity—where do we stand? *J Perinat Med* 2005;33:277–86.
70. Kling PJ, Willeitner A, Dvorak B, et al. Enteral erythropoietin and iron stimulate erythropoiesis in suckling rats. *J Pediatr Gastroenterol Nutr* 2008;46:202–7.
71. Pasha YZ, Ahmadpour-Kacho M, Hajiahmadi M, et al. Enteral erythropoietin increases plasma erythropoietin level in preterm infants: a randomized controlled trial. *Indian Pediatr* 2008;45:25–8.

72. Shiou SR, Yu Y, Chen S, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. *J Biol Chem* 2011;286(14):12123–32.
73. Arsenault JE, Webb AL, Koulinska IN, et al. Association between breast milk erythropoietin and reduced risk of mother-to-child transmission of HIV. *J Infect Dis* 2010;202(3):370–3.
74. Claud EC, Savidge T, Walker WA. Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. *Pediatr Res* 2003;53:419–25.
75. Struck J, Pd Almeida, Bergmann A, et al. High concentrations of procalcitonin but not mature calcitonin in normal human milk. *Horm Metab Res* 2002;34:460–5.
76. Wookey PJ, Turner K, Furness JB. Transient expression of the calcitonin receptor by enteric neurons of the embryonic and early post-natal mouse. *Cell Tissue Res* 2012;347:311–7.
77. Rao RK, Davis TP, Williams C, et al. Effect of milk on somatostatin degradation in suckling rat jejunum in vivo. *J Pediatr Gastroenterol Nutr* 1999;28(1):84–94.
78. Gama P, Alvares EP. LHRH and somatostatin effects on the cell proliferation of the gastric epithelium of suckling and weaning rats. *Regul Pept* 1996;63:73–8.
79. Newburg DS, Woo JG, Morrow AL. Characteristics and potential functions of human milk adiponectin. *J Pediatr* 2010;156(Suppl 2):S41–6.
80. Martin LJ, Woo JG, Geraghty SR, et al. Adiponectin is present in human milk and is associated with maternal factors. *Am J Clin Nutr* 2006;83:1106–11.
81. Woo JG, Guerrero ML, Guo F, et al. Human milk adiponectin affects infant weight trajectory during the second year of life. *J Pediatr Gastroenterol Nutr* 2012;54(4):532–9.
82. Savino F, Sorrenti M, Benetti S, et al. Resistin and leptin in breast milk and infants in early life. *Early Hum Dev* 2012;88:779–82.
83. Savino F, Liguori SA. Update on breast milk hormones: leptin, ghrelin and adiponectin. *Clin Nutr* 2008;27:42–7.
84. Palou A, Sánchez J, Picó C. Nutrient–gene interactions in early life programming: leptin in breast milk prevents obesity later on in life. *Advances in experimental medicine and biology* 2009;646:95–104.
85. Dündar NO, Dündar B, Cesur G, et al. Ghrelin and adiponectin levels in colostrum, cord blood and maternal serum. *Pediatr Int* 2010;52:622–5.
86. Goldman AS. Modulation of the gastrointestinal tract of infants by human milk. Interfaces and interactions. An evolutionary perspective1. *J Nutr* 2000;130:426S–31S.
87. Jarvinen KM, Suomalainen H. Leucocytes in human milk and lymphocyte subsets in cow's milk-allergic infants. *Pediatr Allergy Immunol* 2002;13(4):243–54.
88. Patki S, Kadam S, Chandra V, et al. Human breast milk is a rich source of multipotent mesenchymal stem cells. *Hum Cell* 2010;23(2):35–40.
89. Ichikawa M, Sugita M, Takahashi M, et al. Breast milk macrophages spontaneously produce granulocyte-macrophage colony-stimulating factor and differentiate into dendritic cells in the presence of exogenous interleukin-4 alone. *Immunology* 2003;108(2):189–95.
90. Indumathi S, Dhanasekaran M, Rajkumar JS, et al. Exploring the stem cell and non-stem cell constituents of human breast milk. *Cytotechnology* 2012. [Epub ahead of print].
91. Riskin A, Almog M, Peri R, et al. Changes in immunomodulatory constituents of human milk in response to active infection in the nursing infant. *Pediatr Res* 2012;71(2):220–5.

92. Sabbaj S, Ibegbu CC, Kourtis AP. Cellular immunity in breast milk: implications for postnatal transmission of HIV-1 to the infant. *Adv Exp Med Biol* 2012;743:161–9.
93. Yagi Y, Watanabe E, Watari E, et al. Inhibition of DC-SIGN-mediated transmission of human immunodeficiency virus type 1 by Toll-like receptor 3 signalling in breast milk macrophages. *Immunology* 2010;130(4):597–607.
94. Agarwal S, Karmaus W, Davis S, et al. Immune markers in breast milk and fetal and maternal body fluids: a systematic review of perinatal concentrations. *J Hum Lact* 2011;27(2):171–86.
95. Groer MW, Beckstead JW. Multidimensional scaling of multiplex data: human milk cytokines. *Biol Res Nurs* 2011;13(3):289–96.
96. Kverka M, Burianova J, Lodinova-Zadnikova R, et al. Cytokine profiling in human colostrum and milk by protein array. *Clin Chem* 2007;53(5):955–62.
97. Penttila IA. Milk-derived transforming growth factor- $\beta$  and the infant immune response. *J Pediatr* 2010;156:S21–5.
98. Kalliomäki M, Ouwehand A, Arvilommi H, et al. Transforming growth factor- $\beta$  in breast milk: a potential regulator of atopic disease at an early age. *J Allergy Clin Immunol* 1999;104:1251–7.
99. Saito S, Yoshida M, Ichijo M, et al. Transforming growth factor-beta (TGF- $\beta$ ) in human milk. *Clin Exp Immunol* 1993;94:220–4.
100. Nakamura Y, Miyata M, Ando T, et al. The latent form of transforming growth factor- $\beta$  administered orally is activated by gastric acid in mice. *J Nutr* 2009;139:1463–8.
101. Letterio JJ, Geiser AG, Kulkarni Ashok B, et al. Maternal rescue of transforming growth factor- $\beta$ 1 null mice. *Science* 1994;264:1936–8.
102. Ando T, Hatsushika K, Wako M, et al. Orally administered TGF- $\beta$  is biologically active in the intestinal mucosa and enhances oral tolerance. *J Allergy Clin Immunol* 2007;120:916–23.
103. Ozawa T, Miyata M, Nishimura M, et al. Transforming growth factor- $\beta$  activity in commercially available pasteurized cow milk provides protection against inflammation in mice. *J Nutr* 2009;139:69–75.
104. Donnet-Hughes A, Duc N, Serrant P, et al. Bioactive molecules in milk and their role in health and disease: the role of transforming growth factor- $\beta$ . *Immunol Cell Biol* 2000;78:74–9.
105. Gilmore W, McKelvey-Martin V, Rutherford S, et al. Human milk contains granulocyte colony stimulating factor. *Eur J Clin Nutr* 1994;48(3):222–4.
106. Gersting JA, Kotto-Komeb CA, Dua Y, et al. Bioavailability of granulocyte colony-stimulating factor administered enterally to suckling mice. *Pharmacol Res* 2003;48:643–7.
107. Calhoun DA, Maheshwari A, Christensen RD. Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. *Pediatrics* 2003;112(2):421–3.
108. Gersting JA, Christensen RD, Calhoun DA. Effects of enterally administering granulocyte colony-stimulating factor to suckling mice. *Pediatr Res* 2004;55(5):802–6.
109. Ngom P, Collinson A, Pido-Lopez J, et al. Improved thymic function in exclusively breastfed infants is associated with higher interleukin 7 concentrations in their mothers' breast milk. *Am J Clin Nutr* 2004;80(3):722–8.
110. Aspinnall R, Prentice AM, Ngom PT. Interleukin 7 from maternal milk crosses the intestinal barrier and modulates T-cell development in offspring. *PLoS One* 2011;6(6):e20812.

111. Ustundag B, Yilmaz E, Dogan Y, et al. Levels of cytokines (IL-1beta, IL-2, IL-6, IL-8, TNF-alpha) and trace elements (Zn, Cu) in breast milk from mothers of preterm and term infants. *Mediators Inflamm* 2005;2005(6):331–6.
112. Buescher ES, McWilliams-Koeppen P. Soluble tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) receptors in human colostrum and milk bind to TNF- $\alpha$  and neutralize TNF- $\alpha$  bioactivity. *Pediatr Res* 1998;44:37–42.
113. Buescher E, Malinowska I. Soluble receptors and cytokine antagonists in human milk. *Pediatr Res* 1996;40(6):839–44.
114. Erbağci A, Cekmen M, Balat O, et al. Persistency of high proinflammatory cytokine levels from colostrum to mature milk in preeclampsia. *Clin Biochem* 2005; 38(8):712–6.
115. Meki AR, Saleem TH, Al-Ghazali MH, et al. Interleukins -6, -8 and -10 and tumor necrosis factor alpha and its soluble receptor I in human milk at different periods of lactation. *Nutr Res* 2003;23:845–55.
116. Maheshwari A, Lu W, Lacson A, et al. Effects of Interleukin-8 on the developing human intestine. *Cytokine* 2002;20(6):256–67.
117. Maheshwari A, Lacson A, Lu W, et al. Interleukin-8/CXCL8 forms an autocrine loop in fetal intestinal mucosa. *Pediatr Res* 2004;56(2):240–9.
118. Maheshwari A, Christensen RD, Calhoun DA. ELR+ CXC chemokines in human milk. *Cytokine* 2003;24:91–102.
119. Mizuno K, Hatsuno M, Aikawa K, et al. Mastitis is associated with IL-6 Levels and milk fat globule size in breast milk. *J Hum Lact* 2012;28(4):529–34.
120. Hunt KM, Williams JE, Shafii B, et al. Mastitis is associated with increased free fatty acids, somatic cell count, and interleukin-8 concentrations in human milk. *Breastfeed Med* 2012. [Epub ahead of print].
121. Hrdý J, Novotná O, Kocourková I, et al. Cytokine expression in the colostrum cells of healthy and allergic mothers. *Folia Microbiol (Praha)* 2012;57(3):215–9.
122. Strand TA, Sharma PR, Gjessing HK, et al. Risk factors for extended duration of acute diarrhea in young children. *PLoS One* 2012;7(5):e36436.
123. Lamberti LM, Walker CLF, Noiman A, et al. Breastfeeding and the risk for diarrhea morbidity and mortality. *BMC Public Health* 2011;11(Suppl 3):S15.
124. Brandtzaeg P. The mucosal immune system and its integration with the mammary glands. *J Pediatr* 2010;156(Suppl 2):S8–15.
125. Kadaoui KA, Corthésy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. *J Immunol* 2007;179:7751–7.
126. Corthesy B. Secretory immunoglobulin a: well beyond immune exclusion at mucosal surfaces. *Immunopharmacol Immunotoxicol* 2009;31(2):174–9.
127. Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. *Nutrients* 2011;3(4):442–74.
128. Velona T, Abbiati L, Beretta B, et al. Protein profiles in breast milk from mothers delivering term and preterm babies. *Pediatr Res* 1999;45(5):658–63.
129. Adamkin DH. Mother's milk, feeding strategies, and lactoferrin to prevent necrotizing enterocolitis. *JPEN J Parenter Enteral Nutr* 2012;36:25S–9S.
130. Beljaars L, van der Strate BW, Bakker HI, et al. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. *Antiviral Res* 2004;63(3):197–208.
131. Kuipers ME, de Vries HG, Eikelboom MC, et al. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical *Candida* isolates. *Antimicrob Agents Chemother* 1999;43(11):2635–41.
132. Leitch EC, Willcox MD. Lactoferrin increases the susceptibility of *S. epidermidis* biofilms to lysozyme and vancomycin. *Curr Eye Res* 1999;19(1):12–9.

133. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. *JAMA* 2009;302(13):1421–8.
134. Sherman MP, Bennett SH, Hwang FF, et al. Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and *Lactobacillus GG*. *Bio-metals* 2004;17(3):285–9.
135. Stubbs J, Lekutis C, Singer K, et al. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. *Proc Natl Acad Sci U S A* 1990; 87(21):8417–21.
136. Peterson J, Hamosh M, Scallan C, et al. Milk fat globule glycoproteins in human milk and in gastric aspirates of mother's milk-fed preterm infants. *Pediatr Res* 1998;44(4):499–506.
137. Newburg D, Peterson J, Ruiz-Palacios G, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. *Lancet* 1998;351(9110):1160–4.
138. Aziz M, Jacob A, Matsuda A, et al. Review: milk fat globule-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation. *Apoptosis* 2011;16:1077–86.
139. Shi J, Heegaard CW, Rasmussen JT, et al. Lactadherin binds selectively to membranes containing phosphatidyl-l-serine and increased curvature. *Biochim Biophys Acta* 2004;1667:82–90.
140. Kusunoki R, Ishihara S, Aziz M, et al. Roles of milk fat globule-epidermal growth factor 8 in intestinal inflammation. *Digestion* 2012;85:103–7.
141. Chogle A, Bu H-F, Wang X, et al. Milk fat globule-EGF factor 8 is a critical protein for healing of dextran sodium sulfate-induced acute colitis in mice. *Mol Med* 2011;17(5):502–7.
142. Baghdadi M, Chiba S, Yamashina T, et al. MFG-E8 regulates the immunogenic potential of dendritic cells primed with necrotic cell-mediated inflammatory signals. *PLoS One* 2012;7(6):e39607.
143. Landberg E, Huang Y, Stromqvist M, et al. Changes in glycosylation of human bile-salt-stimulated lipase during lactation. *Arch Biochem Biophys* 2000;377(2): 246–54.
144. Stax MJ, Naarding MA, Tanck MWT, et al. Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. *PLoS One* 2011;6(2):e17316.
145. Naarding MA, Dirac AM, Ludwig IS, et al. Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. *Antimicrob Agents Chemother* 2006;50(10):3367–74.
146. Ruvoen-Clouet N, Mas E, Mariounneau S, et al. Bile-salt-stimulated lipase and mucins from milk of 'secretor' mothers inhibit the binding of Norwalk virus capsids to their carbohydrate ligands. *Biochem J* 2006;393:627–34.
147. Hettinga K, van VH, de VS, et al. The host defense proteome of human and bovine milk. *PLoS One* 2011;6(4):e19433.
148. Saeland E, de Jong MA, Nabatov AA, et al. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. *Mol Immunol* 2009;46:2309–16.
149. Yolken RH, Peterson JA, Vonderfecht SL, et al. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. *J Clin Invest* 1992; 90:1984–7.
150. Parker P, Sando L, Pearson R, et al. Bovine Muc1 inhibits binding of enteric bacteria to Caco-2 cells. *Glycoconj J* 2010;27:89–97.

151. Liu B, Yu Z, Chen C, et al. Human milk mucin 1 and mucin 4 inhibit *Salmonella enterica* serovar *typhimurium* invasion of human intestinal epithelial cells in vitro. *J Nutr* 2012;142:1504–9.
152. Bode L, Kuhn L, Kim HY, et al. Human milk oligosaccharide concentration and risk of postnatal transmission of HIV through breastfeeding. *Am J Clin Nutr* 2012; 96(4):831–9.
153. De Leoz ML, Gaerlan SC, Strum JS, et al. Lacto-N-tetraose, fucosylation, and secretor status are highly variable in human milk oligosaccharides from women delivering preterm. *J Proteome Res* 2012;11(9):4662–72.
154. Hunt KM, Foster JA, Forney LJ, et al. Characterization of the diversity and temporal stability of bacterial communities in human milk. *PLoS One* 2011; 6(6):e21313.
155. Cabrera-Rubio R, Collado MC, Laitinen K, et al. The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. *Am J Clin Nutr* 2012;96(3):544–51.
156. Rasmussen KM, Geraghty SR. The quiet revolution: breastfeeding transformed with the use of breast pumps. *Am J Public Health* 2011;101(8):1356–9.
157. Baro C, Giribaldi M, Arslanoglu S, et al. Effect of two pasteurization methods on the protein content of human milk. *Front Biosci (Elite Ed)* 2011;3:818–29.
158. Chantry CJ, Wiedeman J, Buehring G, et al. Effect of flash-heat treatment on antimicrobial activity of breastmilk. *Breastfeed Med* 2011;6(3):111–6.
159. Israel-Ballard K, Donovan R, Chantry C, et al. Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries. *J Acquir Immune Defic Syndr* 2007;45(3):318–23.
160. Peroni D, Piacentini G, Bodini A, et al. Transforming growth factor- $\beta$ 1 is elevated in unpasteurized cow's milk. *Pediatr Allergy Immunol* 2009;20:42–4.
161. Agennix. Phase 1/2 study of talactoferrin oral solution for nosocomial infection in preterm infants: Available at: <http://clinicaltrials.gov/ct2/show/NCT00854633>. Accessed August 23, 2012.
162. Ewaschuk JB, Unger S, O'Connor DL, et al. Effect of pasteurization on selected immune components of donated human breast milk. *J Perinatol* 2011;31(9): 593–8.
163. Akinbi H, Meizen-Derr J, Auer C, et al. Alterations in the host defense properties of human milk following prolonged storage or pasteurization. *J Pediatr Gastroenterol Nutr* 2010;51(3):347–52.
164. Valentine CJ. Optimizing human milk fortification for the preterm infant. *PNPG Building Block for Life* 2011;34(4):9–11.
165. Steinhoff MC, Omer SB. A review of fetal and infant protection associated with antenatal influenza immunization. *Am J Obstet Gynecol* 2012;207(Suppl 3): S21–7.
166. Neville MC, Anderson SM, McManaman JL, et al. Lactation and neonatal nutrition: defining and refining the critical questions. *J Mammary Gland Biol Neoplasia* 2012;17(2):167–88.
167. Wojcik KY, Rechtman DJ, Lee ML, et al. Macronutrient analysis of a nationwide sample of donor breast milk. *Journal of the American Dietetic Association* 2009; 109(1):137–40.
168. Cianga P, Medesan C, Richardson JA, et al. Identification and function of neonatal Fc receptor in mammary gland of lactating mice. *Eur J Immunol* 1999;29:2515–23.
169. VandePerre P, Simonon A, Karita E, et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. *The Lancet* 1993;341:914–8.

170. Mehta R, Petrova A. Very preterm gestation and breastmilk cytokine content during the first month of lactation. *Breastfeeding Med* 2011;6(1):21–4.
171. Verhasselt V, Milcent V, Cazareth J, et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. *Nat Med* 2008;14(2):170–5.
172. Verhasselt V. Neonatal tolerance under breastfeeding influence: The presence of allergen and transforming growth factor- $\beta$  in breast milk protects the progeny from allergic asthma. *J Pediatr* 2010;156:S16–20.
173. Penttila IA, Flesch IEA, McCue AL, et al. Maternal milk regulation of cell infiltration and interleukin 18 in the intestine of suckling rat pups. *Gut* 2003;52:1579–86.
174. Mosconi E, Rekima A, Seitz-Polski B, et al. Breast milk immune complexes are potent inducers of oral tolerance in neonates and prevent asthma development. *Nat Mucos Immun* 2010;3(5):461–74.
175. Okamoto A, Kawamura T, Kanbe K, et al. Suppression of serum IgE response and systemic anaphylaxis in a food allergy model by orally administered high-dose TGF- $\beta$ . *Int Immunol* 2005;17(6):705–12.
176. Penttila I. Effects of transforming growth factor- $\beta$  and formula feeding on systemic immune responses to dietary b-lactoglobulin in allergy-prone rats. *Pediatr Res* 2006;59(5):650–5.
177. McPherson R, Wagner C. The effect of pasteurization on transforming growth factor alpha and transforming growth factor beta 2 concentrations in human milk. *Adv Exp Med Biol* 2001;501:559–66.
178. Rudloff HE, Schmalstieg FC, Mushtaha A, et al. Tumor Necrosis Factor- $\alpha$  in human milk. *Pediatr Res* 1992;31(1):29–33.
179. Magi B, Ietta F, Romagnoli R, et al. Presence of macrophage migration inhibitory factor in human milk: evidence in the aqueous phase and milk fat globules. *Pediatr Res* 2002;51(5):619–24.
180. Vigh É, Bódis J, Garai J. Longitudinal changes in macrophage migration inhibitory factor in breast milk during the first three months of lactation. *J Reprod Immunol* 2011;89:92–4.
181. Coursodon CF, Dvorak B. Epidermal growth factor and necrotizing enterocolitis. *Curr Opin Pediatr* 2012;24:160–4.
182. Clark JA, Lane RH, et al. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. *Am J Physiol Gastrointest Liver Physiol* 2004;288:G755–62.
183. Untalan PB, Keeney SE, Palkowetz KH, et al. Heat susceptibility of interleukin-10 and other cytokines in donor human milk. *Breastfeeding Med* 2009;4(3):137–44.
184. Ozgurtas T, Aydin I, Turan O, et al. Soluble Vascular Endothelial Growth Factor Receptor 1 in Human Breast Milk. *Horm Res Paediatr* 2011;76:17–21.
185. Chellakooty M, Juul A, Boisen KA, et al. A prospective study of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in 942 healthy infants: associations with birth weight, gender, growth velocity, and breastfeeding. *J Clin Endocrin & Metab* 2006;91(3):820–6.
186. Barezgiamian N, Song J, Jeschke MG, et al. IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis. *J Surg Res* 2006;136:31–7.
187. Barezgiamian N, Song J, Chung DH. Effects of oxidative stress on intestinal type I insulin-like growth factor receptor expression. *Eur J Ped Surg* 2012;22(1):97–104.
188. Juul SE, Christensen RD. Absorption of enteral recombinant human erythropoietin by neonates. *Ann Pharmacother* 2003;37:782–6.

189. Miller-Gilbert AL, Dubuque SH, Dvorak B, et al. Enteral absorption of erythropoietin in the suckling rat. *Pediatr Res* 2001;50(2):261–7.
190. Miller M, Iliff P, Stoltzfus RJ, et al. Breastmilk erythropoietin and mother-to-child HIV transmission through breastmilk. *The Lancet* 2002;360:1246–8.
191. Hirotoni Y, Ikeda K, Kato R, et al. Protective effects of lactoferrin against intestinal mucosal damage induced by lipopolysaccharide in human intestinal Caco-2 cells. *Yakugaku Zasshi* 2008;128(9):1363–8.
192. Buccigrossi V, Marco Gd, Bruzzese E, et al. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. *Pediatr Res* 2007;61(4):410–4.
193. Shah KG, Wu R, Jacob A, et al. Recombinant human milk fat globule-EGF factor 8 produces dose-dependent benefits in sepsis. *Intensive Care Med* 2012;38:128–36.
194. Miksa M, Wu R, Dong W, et al. Dendritic cell derived exosomes containing Milk Fat Globule-Epidermal Growth Factor VIII attenuate proinflammatory responses in sepsis. *Shock* 2006;25(6):586–93.
195. Komura H, Miksa M, Wu R, et al. Milk Fat Globule Epidermal Growth Factor-Factor VIII is down-regulated in sepsis via the lipopolysaccharide-CD14 pathway. *J Immunol* 2009;182:581–7.
196. Miksa M, Wu R, Dong W, et al. Immature dendritic cell-derived exosomes rescue septic animals via Milk Fat Globule Epidermal Growth Factor VIII. *J Immunol* 2009;183:5983–90.
197. Wu R, Dong W, Wang Z, et al. Enhancing apoptotic cell clearance mitigates bacterial translocation and promotes tissue repair after gut ischemia-reperfusion injury. *Int J Mol Med* 2012;30(3):593–8.
198. Matsuda A, Jacob A, Wu R, et al. Milk Fat Globule-EGF Factor VIII in sepsis and ischemia-reperfusion injury. *Mol Med* 2011;17:126–33.
199. Silvestre J-S, Théry C, Hamard G, et al. Lactadherin promotes VEGF-dependent neovascularization. *Nature Med* 2005;11(5):499–506.
200. Woo JG, Guerrero ML, Guo F, et al. Human milk adiponectin affects infant weight trajectory during the second year of life. *JPGN* 2012;54:532–9.
201. Ley SH, Hanley AJ, Stone D, et al. Effects of pasteurization on adiponectin and insulin concentrations in donor human milk. *Pediatr Res* 2011;70(3):278–81.
202. Dündar NO, Dündar B, Cesur G, et al. Ghrelin and adiponectin levels in colostrum, cord blood and maternal serum. *Pediatr Int* 2010;52:622–5.
203. Ozarda Y, Gunes Y, Tuncer GO. The concentration of adiponectin in breast milk is related to maternal hormonal and inflammatory status during 6 months of lactation. *Clin Chem Lab Med* 2012;50(5):911–7.
204. Weyermann M, Brenner H, Rothenbacher D. Adipokines in human milk and risk of overweight in early childhood: a prospective cohort study. *Epidemiol* 2007;18(6):722–9.
205. Marcobal A, Sonnenburg JL. Human milk oligosaccharide consumption by intestinal microbiota. *Clin Microbiol Infect* 2012;18(Suppl 4):12–5.
206. Rudloff S, Kunz C. Milk oligosaccharides and metabolism in infants. *Adv Nutr* 2012;3(3):398S–405S.
207. Ruhaak LR, Lebrilla CB. Analysis and role of oligosaccharides in milk. *BMB Rep* 2012;45(8):442–51.
208. Wang B. Molecular mechanism underlying sialic acid as an essential nutrient for brain development and cognition. *Adv Nutr* 2012;3(3):465S–72S.
209. Coppa GV, Gabrielli O, Zampini L, et al. Glycosaminoglycan content in term and preterm milk during the first month of lactation. *Neonatology* 2012;101(1):74–6.

210. Coppa GV, Gabrielli O, Buzzega D, et al. Composition and structure elucidation of human milk glycosaminoglycans. *Glycobiology* 2011;21(3):295–303.
211. Sando L, Pearson R, Gray C, et al. Bovine Muc1 is a highly polymorphic gene encoding an extensively glycosylated mucin that binds bacteria. *J Dairy Sci* 2009;92:5276–91.
212. Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. *FASEB J* 2008;22:966–81.